Steven Kelly
DirectorMr. Steven Kelly, also known as Steve, is CEO & Director of Actithera, Inc. from September 2026. Mr. Kelly is Director of Carisma Therapeutics, Inc. since March 07, 2023 and also served as its President and Chief Executive Officer since March 07, 2023 until November 15, 2025. He served as President, Chief Executive Officer and Director of CARISMA Therapeutics Inc. since February 2018. Mr. Kelly had been Principal of Kelly BioConsulting, LLC from 2012 to 2018 and served as an independent consultant providing strategic direction and guidance to a variety of life sciences companies. Mr. Kelly served as the Chief Executive Officer and President of Theracrine, Inc. since September 27, 2011. He served as Chief Executive Officer and President of Pinteon Therapeutics, Inc. He served as Chief Commercial Officer of BioVex, Inc., since July 2010. Mr. Kelly was responsible for BioVex's commercial activities as it prepare for the potential launch of BioVex's investigational product, OncoVEX GM-CSF. He served as Chief Executive Officer and President of CytRx Oncology Corporation (formerly, Innovive Pharmaceuticals, Inc.) since June 2004, which he founded. Mr. Kelly joined Innovive in June 2004. He has extensive experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. From November 2002 to May 2004, Mr. Kelly headed the newly created oncology-marketing group for Sanofi-Synthelabo's U.S. division, where he led the launch of Eloxatin™, a treatment of colorectal cancer. He was responsible for launching Eloxatin(R); IDEC Pharmaceuticals and for launching Rituxan(R) and Amgen where he held a variety of commercial and manufacturing roles. He served at IDEC Pharmaceuticals from September 1996 to October 2002, where he served as Director of Marketing. While at IDEC, Mr. Kelly led the launch of Rituxan® in a co-promotion agreement with Genentech. Prior to IDEC, he served as a Process Development and Manufacturing Scientist at Amgen from August 1987 to September 1996, where he served various positions, including roles in Epogen® marketing, new products marketing and manufacturing. He has been an Independent Director of Artelo Biosciences, Inc. since May 2, 2017. He served as a Director of CytRx Oncology Corporation. He served as a Director of Pinteon Therapeutics, Inc. Mr. Kelly has an M.B.A. from Cornell University and a B.S., General Science in Biology and Chemistry, from the University of Oregon.
Positions
- Company NameCarisma Therapeutics, Inc.Stock CodeCARMPositionDirector
- Company NameArtelo Biosciences, Inc.Stock CodeARTLPositionIndependent DirectorColleagues
- GDGregory D. GorgasPresident, CEO, Secretary & Director
- CLConnie L. MatsuiIndependent Chairperson of the Board
- MEMark E. SpringCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
- AYAndrew YatesSenior VP & Chief Scientific Officer
- SDSteven D. ReichChief Medical Officer
- JHJason H. BaybuttSenior Vice President of Finance
- SKSteven KellyIndependent Director
- DWDouglas W. BlayneyIndependent Director
- TATamara A. FavoritoIndependent Director
